MGC Pharmaceuticals - Initial CannEpil purchase orders received
MGC Pharmaceuticals continues to put the building blocks in place for its seed-to-pharmacy medicinal cannabis business. It has received its first formal purchase orders for CannEpil in the UK, and has already received repeat orders from new distributors in Australia. It recently appointed distributors for Brazil, Germany, Austria and Switzerland. Its Phase II study of CogniCann in dementia is recruiting faster than expected. Preliminary approvals are in place for its Malta production hub, but it will need to raise funds for construction. We adjust our valuation to A$157m (vs A$135m).MGC Pharmaceuticals as various inerest in seven prospective gold assets located in the Republic of Senegal, being the Lingokoto, Bouroubourou, Wassadou North and South, Woye, Garaboureya South and Balakonko gold projects.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.